Methods for treating a bioprosthetic tissue and treated bioprosthetic tissue are described. The methods comprise contacting the biological tissue with an anchor compound, the anchor compound comprising first and second functional groups. The first functional group is reactive with and couples a tissue functional group associated with the biological tissue. The second functional group is one of a bio-orthogonal binding pair. The biological tissue coupled to the anchor compound is then exposed to a linking compound. The linking compound comprises at least two functional groups, each comprising the other one of the bio-orthogonal binding pair. In a preferred embodiment, the bio-orthogonal binding pair is an azide and an acetylene. The method can be performed in the presence of a catalyst, preferably a copper catalyst. Alternatively, the method can be performed in the absence of a catalyst, wherein the acetylene is incorporated in a ring-strained cyclic compound, such as cyclooctyne.

A spherical particle comprising decellularized omentum being between 1 nM-300 μM in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.

A spherical particle comprising decellularized omentum being between 1 nM-300 μM in diameter is disclosed. In some embodiments, the particle comprises biological cells. In other embodiments, the particle comprises a biomolecule. Uses of the particles are also disclosed.

The method for decellularization of kidney tissue according to the present invention, the decellularized material produced through the method, and a bioink comprising the decellularized material have the effect of maximizing the effect of kidney treatment by maximizing the content of components specialized for kidney treatment such as the collecting duct and renal tubule of the kidney.

Biphasic tissue constructs that include a scaffold having one or more channels, a vascular portion comprising a hydrogel at least partially disposed in the one or more channels, and a first bioactive growth factor and a second bioactive growth factor different from the first bioactive growth factor, the first bioactive growth factor localized to the scaffold and the second bioactive growth factor localized to the vascular portion. The first bioactive growth factor may be bone morphogenetic protein 2 (BMP2) peptide and the second bioactive growth factor may be vascular endothelial growth factor (VEGF) peptide.

A preparation method of a cross-linked sodium hyaluronate gel is disclosed, which including: preparing an alkaline aqueous solution of hyaluronic acid: formulating a sodium hyaluronate alkali liquor with the concentration of 10-30% g/ml; and carrying out a cross-linking reaction: the cross-linking agent used in the cross-linking reaction being divinyl sulfone or 1,4-butanediol diglycidyl ether, the cross-linking reaction being carried out in an alkaline aqueous solution of hyaluronic acid, the reaction temperature of the cross-linking reaction being 20-40° C., the time of the cross-linking reaction being 4-8 h, and the like. The method of this invention has many advantages, such as easily available raw materials, mild reaction conditions, high cross-linking efficiency, simple process and post-treatment, and easy operation. The obtained cross-linked sodium hyaluronate has a three-dimensional network structure by the crosslinking reaction with good mechanical properties, and can be used as a good drug carrier and a tissue engineering scaffold material.

A system and method for decellularizing tissue is provided. The system includes a pretreatment chamber including a pretreatment solution (e.g., a surfactant), a decellularization solution comprising carbon dioxide and one or more polar solvents, as well as an environmental chamber comprising a treatment chamber. The environmental chamber is maintained at a temperature greater than 31.1° C. and the carbon dioxide is maintained at a pressure greater than 7.38 megapascals to form supercritical CO.sub.2. Tissue treated with the decellularization system and method can contain less than 0.05 micrograms of DNA per milligram of dry tissue after the tissue is exposed to the decellularization solution for a time period ranging from about 1 minute to about 2 hours with minimal ECM fiber disruption. A two-part decellularization solution comprising a surfactant as well as supercritical CO.sub.2 and one or more polar solvents is also provided.

The invention relates to a bioactive bone repair substrate comprising granules obtainable by or obtained from a set solid state mixture of a calcium phosphate based bone repair matrix and a bioactive material, preferably granules having an average diameter between 25 and 10,000 μm.

The present invention is directed to a composition comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. Also disclosed is a tissue graft or implant comprising a matrix suitable for implantation in humans, comprising defatted, shredded, allogeneic human muscle tissue that has been combined with an aqueous carrier and dried in a predetermined shape. The composition and/or tissue graft or implant of the invention is usable in combination with seeded cells, a tissue growth factor, and/or a chemotactic gent to attract a desired cell.

Methods are provided for treatment of several conditions of one or more body features, where the method comprises implanting an acellular soft tissue-derived matrix in, on, proximate to, or a combination thereof, the body feature, wherein the acellular soft tissue-derived matrix comprises a delipidated, decellularized adipose matrix. The delipidated, decellularized adipose tissue matrix is produced by delipidating an adipose tissue sample, followed by decellularizing the delipidated adipose tissue sample. The resulting matrix contains a proportion of lipids which is less than the proportion of lipids contained in a matrix produced by decellularizing an adipose tissue sample prior to delipidating. The delipidated, decellularized adipose matrix may be provided as particles, a slurry, a paste, a gel, an injectable form, or in some other form.